
As an Associate Director, MLOps (Staff AI / ML Engineer) - Indigo AI Innovation Lab, you will play a pivotal role in the advancement of machine learning and AI capabilities across the Alkermes enterprise. You will work closely with our business and technical stakeholders to develop and scale generative AI and ML products and solutions within Alkermes. Your role will involve driving innovation in generative models, designing scalable AI/ML solutions, and collaborating with diverse teams. By architecting and delivering AI and ML products across the enterprise, you will ensure Alkermes' investments in these technologies translate into versatile capabilities for various business needs. Additionally, you will work with internal technical leadership to support Alkermes' AI strategy and technical investments, while contributing to best practices in software engineering and product management. You will support the strategic direction of the AI Innovation Lab and Alkermes’ enterprise data science strategy, and contribute to the development of best practices, standards, and frameworks for data science within the organization. This position will work a hybrid weekly schedule in our Waltham office.
Essential Areas of Responsibility
Basic Qualifications:
Minimum Education & Experience Requirements:
Technical Knowledge/Skills:
Competencies:
Preferred Qualifications:
Personal Attributes:
The annual base salary for this position ranges from $158,000 to $180,000. In addition, this position is eligible for an annual performance pay bonus. Exact compensation may vary based on skills, training, knowledge, and experience. Alkermes offers a competitive benefits package. Additional details can be found on our careers website: www.alkermes.com/careers#working-here

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.
Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment.
Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
See our Community Guidelines: https://www.alkermes.com/social-community-guidelines